A Phase IIb prospective, randomized, double-blind, placebo controlled study of NTx-265: human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in acute ischaemic stroke patients (REGENESIS)

Trial Profile

A Phase IIb prospective, randomized, double-blind, placebo controlled study of NTx-265: human chorionic gonadotropin (hCG) and epoetin alfa (EPO) in acute ischaemic stroke patients (REGENESIS)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs NTx 265 (Primary) ; NTx 265 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms REGENESIS CA
  • Sponsors Stem Cell Therapeutics Inc.
  • Most Recent Events

    • 17 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top